Entera Bio Ltd. Form 8-K Summary
Business Context and Reporting Period
Entera Bio Ltd., an emerging growth company incorporated in Israel, filed this Current Report on Form 8-K on May 27, 2022. The filing addresses a material definitive agreement regarding the company's capital raising mechanisms.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a contractual agreement.
Material Changes
On May 27, 2022, the Company entered into an Amended and Restated At Market Issuance Sales Agreement (the "A&R Sales Agreement") with B. Riley Securities, Inc. This agreement amends the Original Sales Agreement dated May 7, 2021. The primary change effects conforming adjustments necessary because the Company is no longer classified as a foreign private issuer. All other material terms of the original agreement remain unchanged.
Outlook and Risks
The A&R Sales Agreement facilitates the sale of ordinary shares in "at the market offerings" pursuant to Rule 415 under the Securities Act, utilizing a Registration Statement on Form S-3 filed on May 27, 2022. The filing does not provide specific management commentary on future financial performance, risks, or contingencies beyond the standard incorporation of the agreement text.
Investor Verification Checklist
- Verify the full text of the Amended and Restated At Market Issuance Sales Agreement filed as Exhibit 10.1.
- Confirm the status of the Form S-3 Registration Statement filed on May 27, 2022.
- Review the Company's most recent periodic reports (10-K or 20-F) for current financial position and liquidity, as this 8-K contains no financial data.
- Monitor future share issuances under the "at the market" facility for potential dilution.